Gain Therapeutics, Inc.GANXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-14.24%
↓ 204% below average
Average (29q)
13.72%
Historical baseline
Range
High:128.23%
Low:-58.67%
Volatility
1362.6%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -14.24% |
| Q2 2025 | 36.65% |
| Q1 2025 | 99.44% |
| Q4 2024 | -58.67% |
| Q3 2024 | -36.63% |
| Q2 2024 | 71.09% |
| Q1 2024 | 14.62% |
| Q4 2023 | -6.05% |
| Q3 2023 | -37.78% |
| Q2 2023 | 44.94% |
| Q1 2023 | 23.17% |
| Q4 2022 | 13.41% |
| Q3 2022 | -23.61% |
| Q2 2022 | 64.39% |
| Q1 2022 | 5.83% |
| Q4 2021 | -40.35% |
| Q3 2021 | 37.14% |
| Q2 2021 | 29.30% |
| Q1 2021 | 45.70% |
| Q4 2020 | 128.23% |
| Q3 2020 | -2.60% |
| Q2 2020 | 5.18% |
| Q1 2020 | -21.16% |
| Q4 2019 | 33.46% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |